Consensus Guidelines for CSF and Blood Biobanking for CNS Biomarker Studies

Abstract EN

There is a long history of research into body fluid biomarkers in neurodegenerative and neuroinflammatory diseases.

However, only a few biomarkers in cerebrospinal fluid (CSF) are being used in clinical practice.

Anti-aquaporin-4 antibodies in serum are currently useful for the diagnosis of neuromyelitis optica (NMO), but we could expect novel CSF biomarkers that help define prognosis and response to treatment for this disease.

One of the most critical factors in biomarker research is the inadequate powering of studies performed by single centers.

Collaboration between investigators is needed to establish large biobanks of well-defined samples.

A key issue in collaboration is to establish standardized protocols for biobanking to ensure that the statistical power gained by increasing the numbers of CSF samples is not compromised by pre-analytical factors.

Here, consensus guidelines for CSF collection and biobanking are presented, based on the guidelines that have been published by the BioMS-eu network for CSF biomarker research.

We focussed on CSF collection procedures, pre-analytical factors and high quality clinical and paraclinical information.

Importantly, the biobanking protocols are applicable for CSF biobanks for research targeting any neurological disease.